Dr. Jimmy Chang, CEO of TaiMed Biologics, has been invited to speak at the “2026 Taiwan Biotechnology & Healthcare Forum”. Dr. Chang will deliver a featured presentation on March 13, 2026 (Friday), from 14:35 to 14:55, titled:
“From Long-Acting HIV Therapy to Precision Immunotherapy: TaiMed’s Innovative Platform Development Strategy.”
The presentation will provide an in-depth look at how TaiMed leverages its core technology platform to extend its HIV drug development expertise into broader precision immunotherapy applications, while also sharing the company’s strategic positioning within the global biotechnology industry.
Regarding R&D progress, TaiMed stated that enrollment for the Phase 2b clinical trial of its core combination therapy TMB-365/TMB-380 is progressing smoothly and in line with the planned timeline. The company expects to complete patient enrollment in the first half of 2026. The combination therapy aims to provide people living with HIV with a more convenient, low-frequency dosing treatment option. With enrollment progressing as scheduled, TaiMed is steadily advancing toward the next stage of clinical data generation and global licensing negotiations are also currently underway.
In addition, TaiMed’s Board of Directors resolved on March 3, 2026, to implement a share repurchase program to buy back 2,500 lots of the company’s common shares. The company stated that the share repurchase plan is currently being executed as scheduled, reflecting strong confidence in its future operations and long-term value.
TaiMed Biologics has long been committed to the development of innovative antibody therapeutics and continues to advance its drug portfolio through a platform-based strategy. Looking ahead, the company will further strengthen its R&D capabilities and expand international partnership opportunities to enhance its competitiveness in the global biotechnology and healthcare market.
Contact CDMO Service